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poor effect by routine digitalis, diuretic and nitroglycerin therapy,
were recruited into our centre, then were divided into 2 groups
randomly: rhBNP therapy group (n¼31), milrinone therapy
group(n¼31). The frequency of breathing and heart beating, the grade
of NYHA heart function, left ventricular ejection fraction (LVEF), and
the centre venous pressure (CVP), of the patients were observed. The
level of creatinine, alanine aminotransterase (ALT) and NT-proBNP
were measured.
RESULTS The descending frequency of heart beating, the descending
amplitude of the level of creatinine and NT-proBNP, of rhBNP group
were higher than that of milrinone group respectively (25.68.7)
beating/min, (18.57.3) beating/min (p <0.05); (68.211.8)mmol / L,
(46.410.9)mmol / L (p <0.01); (687.7221.5) ng / L, (430.4170.9)ng /
L (p <0.01). The elevating amplitude of the LVEF of rhBNP
group also were higher than that of milrinone group respectively
(8.14.7)%,(5.53.3)%(p <0.05)0. There were no difference in the
altered levels of alanine aminotransterase, the descending
amplitude of CVP, the descending frequency of breathing, and the
descending grade of NYHA heart function, between two groups
respectively (56.410.3) u/l,(47.812.6) u/l (p >0.05);(5.43.3)
cmH2O,(4.02.8)cmH2O (p>0.05); (15.18.7)/min,(12.59.3)/min
(p>0.05);(1.30.3),(1.00.4) (p >0.05).
CONCLUSIONS The rhBNP is efﬁcacy and safe for acute decom-
pensated ischemic heart failure.
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OBJECTIVES The purpose of this study was to evaluate the effect of
carvedilol on b2-adrenoceptor density in erythrocyte membranes of
post-MI patients with chronic heart failure (CHF).
METHODS The study included 56 post-MI male patients aged from 45
to 55 (mean age 51.24.6 years) years with CHF FCII-III; duration of
post-MI period was 2.30.9 years. All the patients were divided into
two groups according to the New York Heart Classiﬁcation (NYHA)
functional class (FC). Group 1 consisted of 30 post-MI patients with
CHF FC-II and Group 2 consisted of 26 post-MI patients with CHF-III.
The b2-adrenoceptor density in erythrocyte membranes was deter-
mined using b-APM-AGAT kits. All patients received a carvedilol,
nonselective beta blocker with a1-, b1- and b2- blocking properties, on
the background of basic therapy (ACE inhibitors, spironolactone, ni-
trates, aspirin, loop diuretics). Initial carvedilol dosage was 3.125 mg
and was titrated to achieve the target dosage of 25–50 mg twice a day.
Mean carvedilol dosage was 23.84.6 mg/day in Group 1 and
33.656.9 mg/day in Group II. Exclusion criteria were diabetes, heart
rhythm disorders, COPD, asthma, and acute stroke.
RESULTS In Group 1 patients, the initial erythrocyte b2-adrenoceptor
density was 27.71.4CU and exceeded the control value group by 2.4
times; in Group 2 patients it was 30.81.3CU and exceeded the control
value by 2.9 times. Our studies have shown that therapy with carve-
dilol for 6 months led to a decrease of b2-adrenoceptor density by
15.7% (P<0.05) in post-MI patients with CHF FC-II and by 22.7%
(P<0.05) in post-MI patients with CHF FC-III in comparison with the
initial levels.
CONCLUSIONS In conclusion, in post-MI patients with CHF FC I-III,
the increased b2-adrenoceptor density, which is more pronounced in
patients of Group 2. Long-term therapy with carvedilol reduces the b2-
adrenoceptor density in erythrocyte membranes of post-Mi patients
with CHF FCII-III.
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OBJECTIVES To explore the clinical effects of Cardiac resynchroni-
zation therapy (CRT) in patients with chronic heart failure.METHODS 6 cases which received CRT by cardiology department 2
from January 2014 to January 2015 were selected, 4 cases with dilated
cardiomyopathy, 2 cases with ischemic cardiomyopathy; 5 cases were
males and 1 case were female; 5 cases with left bundle branch
block(LBBB);mean range was 52-70 years. Inclusion criteria:
1. after optimization drug treatment, the heart of New York (NAHY)
levels were still at III to IV;
2. left ventricular end diastolic diameter (LVEDd)55mm, left ventric-
ular ejection fraction(LVEF)35%;
3. the ventricular wall have were incoordination;
4. QR S duration 120 ms;
5. sinus rhythm.
The medical history of the patients with heart failure were greater
than 1 year, and the symptom of heart failure were still 6 existing after
drug treatment. 5 cases NYHA class were III, 1 case was IV. The
pacemaker wires inserted in auricula dextra, right ventricular apex,
Coronary sinus collateral or dexterramus through left subclavian vein.
The implantation left ventricular pacing lead: To understand the di-
rection of blood vessels by using coronary sinus imaging, and choose
the best location according to the results of the pacemaker parameters
and imaging.The pacemaker wires inserted in collateral or back of the
coronary sinus, the pacing thresholds were satisﬁed. Then, the right
ventricle and right atrium wires were inserted, and to test the Pace-
maker threshold and perception parameters. Lastly, the pacemaker
wires were connected to pacemaker, and the pacemaker was
implanted in the left side of pectoralis major., and sew up the incision.
The A-V period and V-V period were optimized after 1 week, 1 month,
3 month, 6 month, 12 month. To observe the cardiac function, QRS
duration, LVEF, LVEDd after 64.3 month follow-up. Using SPSS13.0
software for statistical analysis, measurement data said with 0xs, and
then compared by t-test, P < 0.05 for statistical signiﬁcance.
RESULTS The implantations of CRT were successful, and the NYHA
class were great improvement from III - IV to I-II (p <0.05), the QRS
duration was signiﬁcant decreased from 14912.4ms to 117.24.8ms
(p <0.05), the LVEF was great improved from 0.280.06 to 0.480.06
(p <0.05), and the LVEDd was signiﬁcant decreased from 69.96.4mm
to 51.06.7mm, (p <0.01).
CONCLUSIONS The cardiac resynchronization therapy conbine drug
treatment could improve cardiac function, alleviate clinical symptoms
in patients with chronic heart failure, and improve the patient’s
quality of life.
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OBJECTIVES To explore whether the phosphoinositide 3-kinase /
protein kinase B (PI3K/AKT) signaling pathway was related to the
occurrence of isoproterenol (ISO) induced Cardiac Cachexia.
METHODS One hundred male Sprague-Dawey rats were randomly
divided into ISO group and control group. In ISO group, the rats were
administered with ISO of 180mg/kg$d via inguinal subcutaneous in-
jection, once every other day, 2 times in all. After 4 weeks, the heart
function of was measured by echocardiography. All rats were
weighted before injecting ISO and after 4 weeks. According to the
changes of body weight and the echocardiography results, ISO group
were divided into cardiac cachexia group (n¼29) and heart failure non
cachexia group (n¼40). The levels of total protein, triglycerides,
cholesterol and blood glucose were detected by using automatic
biochemical analyzer. The levels of insulin and Insulin-like growth
factor-1 (IGF-1) in the serum of all rats were detected by enzyme-
linked immunosorbent assay (ELISA); the expression of p85, p-Akt
and NF-kB in the myocardial tissue were detected by immunohisto-
chemical; the expression of caspase9 mRNA and Bcl-xl mRNA in the
myocardial tissue were detected by reverse transcription polymerase
chain reaction (RT-PCR).
RESULTS (1) The levels of LVEDD, LVESD increased signiﬁcantly and
LVEF, FS decreased signiﬁcantly in ISO group(P <0.05) (2) the levels
of total protein, blood glucose decreased signiﬁcantly and tri-
glycerides, cholesterol increased signiﬁcantly in ISO group compared
with control group (P <0.05) (3) the levels of insulin in cardiac
cachexia group(30.85þ1.90 mIU/L) was signiﬁcantly higher than in the
heart failure non cachexia group(19.56þ5.33 mIU/L) and control group
(27.45þ5.36 mIU/L) (P <0.05), (4) the levels of IGF-1 in cardiac
